Activity Summary:
The Clinical Viewpoints Hereditary Angioedema lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slides developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Hereditary angioedema (HAE) is a potentially life-threatening genetic condition that presents many unique challenges. The diagnosis of HAE is based on suggestive clinical history and physical findings. In addition, optimal management relies on a patient-centered and shared decision-making approach despite the recent significant advances in treatment options. This activity uses a case-based approach to discuss new and existing diagnostic approaches, options for on-demand medications, and individualized strategies for long-term management.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Clinical Viewpoints Hereditary Angioedema lecture library includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert faculty. The slides will be continuously evaluated and updated for current relevance.

Activity Summary:
The Clinical Viewpoints Hereditary Angioedema lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slides developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

The field of hereditary angioedema (HAE) has recently evolved with the advent of new and forthcoming diagnostic and treatment measures. In particular, the shift toward oral medications will most certainly improve the quality of life for HAE patients. This lecture provides an overview of current diagnostic and treatment procedures recommended by the World Allergy Organization (WAO) and the United States Hereditary Angioedema Association Medical Advisory Board (US HAEA MAB) and summarizes forthcoming new advances in the field of HAE.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.